NASDAQ: BIOM WARUM JETZT KAUFEN!?!?! - 500 Beiträge pro Seite

[BIOM]

NASDAQ: BIOM





Agree, $10 short term very likely especially with an early approval anywhere.

BLP25 alone could be a $1b drug. Even if we assume it wont be on the market for 5-7 years.
Here`s my projection with very conservative assumptions:

Assumptions.
Another phase 3 to take 7 years for approval
$1B sales 5 years after approval so 12 years from now.
200 million shares o.s in 12years.
50% share of sales with MERCK Kgaa.
Price to sales ratio 20x
Discount rate 20%

Heres the math
(1000/200)x50%x 20x sales=$50.00/share in 12 years.
discount by 20%/year to present value:
$50 x .8^12 =$3.43/share now.

dies habe ich auf einer Yahoo Seite gefunden!!!
könnt unter : http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=… selber nachlesen.

Ich denke das in der nächsten Zeit einige Meldungen kommen werden. Aufsteigende Kurse!! Mein Tipp: 50% in 2 Wochen, 100% bis Ende des Jahres!
aktueller Kurs:

[BIOM]

BIOMIRA (2Jahre)

[BIOM]

Biomira`s Upside Year End Potential

[BIOM]

INSTITUTE CANCER IMMUNOTHERAPEUTICS CONFERENCE

Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) announced that Rao Koganty, Ph.D., Senior Director, Research and Development and Chemistry will present at the upcoming Cambridge Healthtech Institute Cancer Immunotherapeutics Conference, September 20-21, 2004 at the Fairmont Copley Plaza, Boston, MA. Dr. Koganty’s presentation entitled, “Receptors of the Immune System and Their Ligands: Immunotherapy of Cancers” will kick off the conference following the Chairperson’s opening remarks and will commence at 8:30 EST on Monday, September 20th.

Dr. Koganty and his staff at Biomira have developed several classes of synthetic adjuvants that target the receptors of the immune system such as the toll like receptors (TLR). These synthetic adjuvants, when formulated in combination with well-defined synthetic antigens, are expected to consistently generate specific immune responses to attack cancer cells as well as bacterial and viral pathogens that cause infectious diseases. Chemically well defined synthetic adjuvants open doors for the development of molecular vaccines that are highly specific and definable in the near future. Biomira develops such synthetic adjuvants for outlicensing and commercial resale.

“We were pleased to learn that Dr. Koganty’s work will be highlighted at this scientific forum,” said Alex McPherson, MD, PhD, President and CEO. “ His work is important in Biomira’s quest to find better treatments for cancer patients. Dr. Koganty’s work in carbohydrate vaccines was also recently featured as part of the cover story in the August 9th edition of the prestigious Chemical and Engineering News.”

[BIOM]

Biomira Inc. (BIOM) (CA:BRA) and its collaborator, Merck KGaA of Darmstadt, Germany, announced today that data from the Companies` Phase IIb BLP25 Liposome vaccine (L-BLP25) trial has been accepted as the subject of a presentation at the 2004 Meeting of the European Society for Medical Oncology (ESMO). The 29th ESMO Congress is to take place in Vienna, Austria, October 29 - November 2, 2004. The lead investigator for the Phase IIb trial and scheduled ESMO presenter is Dr. Charles Butts, Medical Oncologist, of the Cross Cancer Institute, Edmonton, Alberta. Dr. Butts` presentation is planned for November 1, 2004, at 3:25 p.m. (Austrian time: GMT +1). The presentation is entitled, "A multicenter phase IIb randomized study of liposomal MUC1 vaccine for immunotherapy of non-small cell lung cancer (NSCLC); L-BLP25 Non-Small Cell Lung Cancer Study Group."

[BIOM]

Hab ich es Euch nicht gesagt, die Rakete zündet!